In a December 2024 Ipsos survey of over 2,000 UK adults, people still say they would prefer to lose weight without using medications
pelvic inflammatory disease, pelvic adhesions, ovarian cysts or masses, leiomyomata, and adenomyosis) and non-gynecologic conditions and factors (e.g
Images of medication Mounjaro Generic Name tirzepatide Strength 15 mg/0.5 mL pre-filled single-dose pen Availability Prescription only Drug Class GLP-1 Drugs CSA Schedule Not a controlled drug Labeler / Supplier Eli Lilly and Company National Drug Code (NDC) 00002-1457 More about Mounjaro (tirzepatide) Check interactions Compare alternatives Pricing & coupons Reviews (2,083) Drug images Latest FDA alerts (2) Side effects Dosage information Patient tips During pregnancy Support group FDA approval history Drug class: GLP-1 Drugs Breastfeeding En espaol Patient resources Other brands Professional resources Other brands Related treatment guides Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
The peptide concentration determines what each unit actually delivers in terms of milligrams
Based on Kaiser formulary bulletins and member-reported experiences, most regions require the following before approving Wegovy: Clinical eligibility: BMI of 30 kg/m or greater, or BMI of 27 kg/m or greater with at least one weight-related condition (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea) Documentation that the member has participated in a Kaiser-affiliated lifestyle or behavioral weight-management program for a minimum of 3 to 6 months Lab work within the past 6 months including fasting glucose, HbA1c, lipid panel, and thyroid function Prescriber requirements: The prescribing physician must be a Kaiser-employed or contracted provider A referral to Kaiser's obesity-medicine or endocrinology department is typically required before the PA can be submitted The obesity-medicine specialist's notes must confirm medical necessity The clinical rationale for these layers traces back to the STEP-1 trial (N=1,961), which demonstrated 14.9% mean body-weight loss with semaglutide 2.4 mg at 68 weeks versus 2.4% with placebo
Deanne Jade, director of the National Centre for Eating Disorders, said: Its like handing a loaded gun to people with eating disorders
